ERBB2 and neoplasm: Then, in an attempt to identify factors which may predict changes in the HER2 status between primary and recurrent tumours, we analysed clinical, pathological and immunohistochemical characteristics for patients with HER2-negative primary tumours who developed local recurrences compared to those with distant metastases.